A new first-in-class therapy targets MYC, a cancer protein long seen as 'undruggable.' In early lab tests, it showed promise against hard-to-treat blood cancers at MD Anderson in Houston.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
First-in-class therapy targets 'undruggable' protein in hard-to-treat blood cancers
MYC Target protein
Blood Cancers Cancers treated
Preclinical Study type
Blood Journal Published in